Norway · Delayed Price · Currency is NOK EXACT Therapeutics AS Earnings Call Transcripts
Fiscal Year 2026
-
Plans to delist from Euronext Growth are driven by low liquidity and the need to attract VC funding for phase III trials. Clinical progress in pancreatic cancer is strong, with promising early results and ongoing phase II enrollment. Minority shareholders will retain rights but must trade shares privately after delisting.
-
A proprietary ultrasound-activated drug delivery platform is showing promising early results in phase II trials for locally advanced pancreatic cancer, with significant tumor shrinkage and biomarker reduction. Financial runway is secured into 2027, supporting clinical and platform expansion.
Fiscal Year 2024
-
A $13 million private placement, led by GE HealthCare, secures funding for a phase II pancreatic cancer trial using Acoustic Cluster Therapy, which has shown strong efficacy and safety signals. Orphan drug designation and strategic partnerships position the company for accelerated approval and significant market opportunity.